Home
Account
Research Tools
Educate
Contribute
News
Sectors
Premium
About Us
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Chart School
Tutorials
Learning Center
Glossary
Submit Article
Join Blog Network
Rate Broker
Rate Software
Earnings
Dividend
Management Changes
M&A
Analyst
FDA
IPO
About Us
Contact Us
Advertise With Us
Editorial Staff
Terms and Conditions
Privacy Policy
iStock Rating
C
Details...
Enter Symbol
Novartis AG (NYSE: NVS)
Sector: Medical
Current Price :
$51.96
52 Week Low
$51.65
52 Week High
$64.52
Company
Overview
Research Notes
Company Profile
Competitors
Community
Wiki
Stock Sentiment
Whisper Estimates
Enter Estimates
Message Board
Analysis
Related News
Blog Articles
Press Releases
Charts
Technical Charts
Analyst
Analyst Ratings
Analyst Estimates
Sales Estimates
Ratios
Financial Ratios
Technicals
Shares Outstanding:
2406M
Market Cap:
$130.85B
Avg Volume:
2680314
P/E Ratio:
10.680
PEG Ratio:
2.380
Split:
On 5/11/2000 nvs split by factor of 2.000
Trade now with
1m
3m
6m
1y
2y
Opinion and Analysis
Gilead’s Hematology Pipeline - Transformative And Under-Appreciated
May 09, 2012 10:45 AM |
EXEL
,
GILD
,
INCY
,
NVS
,
PCYC
,
RIGL
Endo Pharmaceuticals (ENDP) Posts In-Line Q1 Earnings
May 01, 2012 09:34 AM |
ENDP
,
IPXL
,
NVS
Novartis (NVS) Gains After Afinitor Drug Approved By FDA To Treat Kidney Tumors
Apr 26, 2012 11:42 PM |
NVS
Mylan (MYL): FDA Approves Generic Version Of Lescol Capsules
Apr 13, 2012 07:48 AM |
MYL
,
NVS
Healthcare Reform: Bad News For Big Pharma?
Apr 02, 2012 04:23 PM |
ABT
,
AZN
,
CIA
,
JNJ
,
LLY
,
MRK
More Articles on NVS..
Market News
Pfizer 3Q profit up on higher sales, lower charges
Nov 01, 2011 02:37 PM |
NVS
,
PFE
Stocks cautious ahead of Europe debt plan
Oct 25, 2011 07:39 AM |
NVS
,
UBS
Novartis fights patent rejection in Indian court
Sep 06, 2011 06:43 AM |
NVS
INDIA: EU Trade Deal May Curb Affordable Drug Supply
Mar 24, 2011 05:55 AM |
ABT
,
NVS
Global economy, price pressures ail drugmakers
Jan 27, 2011 05:52 PM |
AZN
,
BMY
,
JNJ
,
LLY
,
NVS
More News on NVS..
Press Releases
Novus Energy Inc. announces first quarter 2012 results and re-affirms guidance for 2012
May 15, 2012 08:00 AM |
NVS
Novartis drug Afinitor? approved by FDA as first medication to treat patients with non-cancerous kidney tumors associated with TSC
Apr 26, 2012 06:18 PM |
NVS
Novus Energy Inc. Announces Appointment of Chairman and Grants Incentive Stock Options
Apr 20, 2012 12:28 PM |
NVS
More Press Releases on NVS..
SEC Filings
More SEC Filings on NVS..
Sentiment Survey
Avg. Short Term
Avg. Long Term
Avg. Grade
More Details
Share Performance
Period
NVS
Compare to S&P
YTD
-4.90 %
-13.08 %
4 Weeks
-0.64 %
0.28 %
12 Weeks
-3.84 %
-5.09 %
More...
Financial Ratios
Earnings Performance
EPS Growth in Last Quarter:
-22.76 %
EPS Growth in Last Year:
-32.14 %
Sales Growth in Last Quarter:
-7.08 %
Sales Growth in Last Quarter:
-2.08 %
More...
Fundamental data is provided by
Zacks Investment Research
, and Commentary, news and Press Releases provided by YellowBrix and
Quotemedia
. Advertisement partners
Investing Channel
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##